Back to top

Image: Bigstock

Jazz Pharmaceuticals Public Limited Company

Read MoreHide Full Article

Jazz’s third-quarter results were encouraging with the company reporting year-over-year growth in both earnings and revenues. Xyrem and other key products like Erwinaze and Defitelio continued to perform well. Moreover, the company’s intention to diversify its portfolio through business development deals is encouraging. However, patent litigations related to Xyrem continue to be an overhang. The narrowed outlook for 2015 is also disappointing. In addition, the suspension of patient enrolment in a phase II study on leukemia candidate, JZP-416, and the decision against moving sleep disorder candidate, JZP-386 and hematology candidate, Leukotac, into the next stage of development are concerning.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ) - free report >>